Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873725 | 0.85 | TSHR (0.45) | ALDH1A1TSHRHTT | |
| SCHEMBL17818667 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRHTT | |
| SCHEMBL17975859 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRHTT | |
| SCHEMBL8815411 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHRHTT | |
| Boric Acid SCHEMBL28756071 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL11131461 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL10544728 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL9413907 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TSHRHTT | |
| Lithium Ion SCHEMBL28756070 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TSHRHTT | |
| SCHEMBL28248190 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0262305-B1 | METHOD FOR THE PREPARATION OF ANILINOFUMARATE AND QUINOLINE-2,3-DICARBOXYLIC ACID | AMERICAN CYANAMID COMPANY (US) | 1990-10-31 | — | — | EP | claimed |
| EP-0262305-A1 | Method for the preparation of anilinofumarate and quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID COMPANY (US) | 1988-04-06 | — | — | EP | claimed |
| US-20130210786-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | PHYTOPHARM PLC (GB) | 2013-08-15 | — | — | US | disclosed |
| EP-2595621-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | Phytopharm PLC (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20120034193-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | PHYTOPHARM PLC (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2012010896-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | PHYTOPHARM PLC (GB) | 2012-01-26 | — | — | WO | disclosed |
| EP-2389182-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | Phytopharm PLC (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-20110254980-A1 | IMAGE PROCESSING METHOD AND APPARATUS | MAUNA KEA TECHNOLOGIES (FR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010084356-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | PHYTOPHARM PLC (GB) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034193-A1 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS | BDNF, NGF, GFRA1 | ALDH1A1 878/4885TSHR 2367/4885HTT 4231/4885 |
| US-20130210786-A1 | TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS | SNCA, DBH, COMT | ALDH1A1 210/4885TSHR 1166/4885HTT 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.